Furthermore, FoxO1 inhibition reduced the viability of CLL cells cocultured with stromal cells and CLL cell proliferation induced by the T cell factors (CD40L, IL-4, and IL-21), and this was potentiated in combination with ibrutinib. Here, IL21 is linked to B-cell chronic lymphocytic leukemia.